Prevalence, Predictors, and Outcomes of Premature Discontinuation of Thienopyridine Therapy After Drug-Eluting Stent Placement: Results From the PREMIER Registry

Background— Although drug-eluting stents (DES) significantly reduce restenosis, they require 3 to 6 months of thienopyridine therapy to prevent stent thrombosis. The rate and consequences of prematurely discontinuing thienopyridine therapy after DES placement for acute myocardial infarction (MI) are unknown. Methods and Results— We used prospectively collected data from a 19-center study of MI patients to examine the prevalence and predictors of thienopyridine discontinuation 30 days after DES treatment. We then compared the mortality and cardiac hospitalization rates for the next 11 months between those who stopped and those who continued thienopyridine therapy. Among 500 DES-treated MI patients who were discharged on thienopyridine therapy, 68 (13.6%) stopped therapy within 30 days. Those who stopped were older, less likely to have completed high school or be married, more likely to avoid health care because of cost, and more likely to have had preexisting cardiovascular disease or anemia at presentation. They were also less likely to have received discharge instructions about their medications or a cardiac rehabilitation referral. Patients who stopped thienopyridine therapy by 30 days were more likely to die during the next 11 months (7.5% versus 0.7%, P<0.0001; adjusted hazard ratio=9.0; 95% confidence interval=1.3 to 60.6) and to be rehospitalized (23% versus 14%, P=0.08; adjusted hazard ratio=1.5; 95% confidence interval=0.78 to 3.0). Conclusions— Almost 1 in 7 MI patients who received a DES were no longer taking thienopyridines by 30 days. Prematurely stopping thienopyridine therapy was strongly associated with subsequent mortality. Strategies to improve the use of thienopyridines are needed to optimize the outcomes of MI patients treated with DES.

[1]  M. Eisenberg Drug-eluting stents: some bare facts , 2004, The Lancet.

[2]  P. Serruys,et al.  Short- and Long-Term Clinical Outcome After Drug-Eluting Stent Implantation for the Percutaneous Treatment of Left Main Coronary Artery Disease: Insights From the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital Registries (RESEARCH and T-SEARCH) , 2005, Circulation.

[3]  S. Connolly,et al.  Poor adherence to placebo or amiodarone therapy predicts mortality: results from the CAMIAT study. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. , 1999, Psychosomatic medicine.

[4]  I. Iakovou,et al.  Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. , 2005, JAMA.

[5]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[6]  D. Baim,et al.  Stent Thrombosis in the Modern Era: A Pooled Analysis of Multicenter Coronary Stent Clinical Trials , 2001, Circulation.

[7]  P. Burkhart,et al.  Adherence to long-term therapies: evidence for action. , 2003, Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing.

[8]  Sankey V. Williams,et al.  ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). , 2003, Circulation.

[9]  Deepak L. Bhatt,et al.  What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis. , 2005, Journal of the American College of Cardiology.

[10]  Ousa,et al.  A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION , 2002 .

[11]  R. Spitzer,et al.  The PHQ-9: validity of a brief depression severity measure. , 2001, Journal of general internal medicine.

[12]  C. Viscoli,et al.  Treatment adherence and risk of death after a myocardial infarction , 1990, The Lancet.

[13]  Marco Valgimigli,et al.  The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. , 2005, Journal of the American College of Cardiology.

[14]  David J Cohen,et al.  Stent Thrombosis After Successful Sirolimus-Eluting Stent Implantation , 2004, Circulation.

[15]  D. Kandzari,et al.  Late thrombosis following treatment of in‐stent restenosis with drug‐eluting stents after discontinuation of antiplatelet therapy , 2005, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[16]  L. Goldman,et al.  The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. , 1996, JAMA.

[17]  Carl J Pepine,et al.  ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients , 2002, Circulation.

[18]  M. McDermott,et al.  Impact of medication nonadherence on coronary heart disease outcomes. A critical review. , 1997, Archives of internal medicine.

[19]  Eric Peterson,et al.  The Prospective Registry Evaluating Myocardial Infarction: Events and Recovery (PREMIER)--evaluating the impact of myocardial infarction on patient outcomes. , 2006, American heart journal.

[20]  Salim Yusuf,et al.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study , 2001, The Lancet.

[21]  A. Murphy,et al.  Secondary prevention of coronary heart disease: patient beliefs and health-related behaviour. , 2005, Journal of psychosomatic research.

[22]  D. Sackett,et al.  Can Simple Clinical Measurements Detect Patient Noncompliance? , 1980, Hypertension.

[23]  Sunil J Rao,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2003 .

[24]  K. Mahaffey,et al.  Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial. , 2002, American heart journal.

[25]  S. De Geest,et al.  Adherence to Long-Term Therapies: Evidence for Action , 2003, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[26]  P. R. R. Ecurrent,et al.  EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .

[27]  A. Lippman Adherence to medication. , 2005, The New England journal of medicine.

[28]  M. Bell,et al.  Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement. , 1999, Circulation.

[29]  Gervasio A. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[30]  J. W. Schaeffer,et al.  ACC/AHA guidelines for the management of patients with unstable angina and non‐ST segment elevation myocardial infarction: Executive summary and recommendations , 2000, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[31]  William A. Knaus,et al.  The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. , 1996, Journal of the American Medical Association (JAMA).

[32]  L. Goldman,et al.  The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. , 1996, JAMA.

[33]  S. Normand,et al.  American College of Cardiology and American Heart Association methodology for the selection and creation of performance measures for quantifying the quality of cardiovascular care. , 2005, Journal of the American College of Cardiology.

[34]  R. Ferrari,et al.  Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. , 2005, JAMA.

[35]  Fernando Alfonso,et al.  Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. , 2005, Journal of the American College of Cardiology.

[36]  P. Serruys,et al.  Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. , 2005, Journal of the American College of Cardiology.

[37]  Jeffrey W Moses,et al.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.

[38]  Patrick W Serruys,et al.  Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy , 2004, The Lancet.